Valley National Advisers’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.2M Sell
7,859
-30
-0.4% -$4.6K 0.16% 128
2025
Q4
$1.09M Buy
7,889
+5
+0.1% +$655 0.15% 128
2025
Q3
$1.01M Sell
7,884
-149
-2% -$18.2K 0.16% 128
2025
Q2
$972K Sell
8,033
-809
-9% -$91.2K 0.16% 130
2025
Q1
$984K Sell
8,842
-310
-3% -$33K 0.18% 129
2024
Q4
$889K Sell
9,152
-685
-7% -$73K 0.16% 127
2024
Q3
$1.13M Sell
9,837
-6,957
-41% -$789K 0.2% 123
2024
Q2
$1.79M Sell
16,794
-351
-2% -$35.2K 0.27% 81
2024
Q1
$1.66M Sell
17,145
-304
-2% -$31.2K 0.25% 81
2023
Q4
$1.76M Sell
17,449
-700
-4% -$67.6K 0.28% 77
2023
Q3
$1.85M Sell
18,149
-1,118
-6% -$113K 0.32% 67
2023
Q2
$1.95M Sell
19,267
-1,009
-5% -$101K 0.33% 62
2023
Q1
$2.04M Sell
20,276
-484
-2% -$42.3K 0.36% 61
2022
Q4
$1.88M Sell
20,760
-419
-2% -$35.3K 0.34% 69
2022
Q3
$1.64M Sell
21,179
-166
-0.8% -$13.8K 0.34% 68
2022
Q2
$1.8M Buy
21,345
+201
+1% +$17.6K 0.38% 60
2022
Q1
$1.85M Sell
21,144
-65
-0.3% -$5.63K 0.36% 65
2021
Q4
$1.85M Sell
21,209
-374
-2% -$31.1K 0.34% 78
2021
Q3
$1.76M Sell
21,583
-95
-0.4% -$8.55K 0.32% 86
2021
Q2
$1.98M Sell
21,678
-165
-0.8% -$14.7K 0.36% 73
2021
Q1
$1.87M Sell
21,843
-367
-2% -$32.9K 0.36% 70
2020
Q4
$2.1M Sell
22,210
-575
-3% -$50.2K 0.44% 40
2020
Q3
$1.98M Sell
22,785
-1,065
-4% -$92.3K 0.45% 36
2020
Q2
$2.08M Sell
23,850
-1,094
-4% -$94.4K 0.48% 38
2020
Q1
$2.06M Sell
24,944
-1,651
-6% -$147K 0.57% 37
2019
Q4
$2.52M Sell
26,595
-7
-0% -$628 0.63% 37
2019
Q3
$2.31M Sell
26,602
-97
-0.4% -$8.71K 0.63% 37
2019
Q2
$2.44M Sell
26,699
-3,633
-12% -$307K 0.67% 39
2019
Q1
$2.61M Sell
30,332
-1,957
-6% -$157K 0.75% 35
2018
Q4
$2.48M Sell
32,289
-337
-1% -$26.2K 0.81% 35
2018
Q3
$2.52M Sell
32,626
-248
-0.8% -$18.3K 0.87% 33
2018
Q2
$2.23M Sell
32,874
-472
-1% -$32.6K 0.85% 35
2018
Q1
$2.42M Sell
33,346
-203
-0.6% -$15.5K 0.9% 29
2017
Q4
$2.52M Sell
33,549
-644
-2% -$48.6K 0.88% 27
2017
Q3
$2.63M Sell
34,193
-2,031
-6% -$153K 0.9% 19
2017
Q2
$2.71M Sell
36,224
-3,241
-8% -$230K 0.97% 19
2017
Q1
$2.63M Sell
39,465
-6,071
-13% -$405K 1% 20
2016
Q4
$2.97M Sell
45,536
-3,245
-7% -$211K 1.37% 21
2016
Q3
$3.45M Buy
48,781
+22,433
+85% +$1.63M 1.78% 14
2016
Q2
$1.95M Buy
26,348
+6,090
+30% +$421K 1.01% 29
2016
Q1
$1.31M Sell
20,258
-28
-0.1% -$1.91K 0.71% 43
2015
Q4
$1.56M Buy
20,286
+1,193
+6% +$94.8K 0.92% 32
2015
Q3
$1.57M Sell
19,093
-231
-1% -$20.6K 0.95% 31
2015
Q2
$1.7M Sell
19,324
-312
-2% -$28.6K 0.96% 31
2015
Q1
$1.74M Sell
19,636
-235
-1% -$20.8K 1.02% 29
2014
Q4
$1.43M Buy
+19,871
New +$1.65M 1.08% 29

Other funds holding NVS

Valley National Advisers's NVS Position: Q1 2026 in Review

Valley National Advisers reduced its Novartis (NVS) stake by 0.38% in Q1 2026, selling an estimated $4.6K and leaving 7,859 shares worth $1.2M. The position accounts for 0.16% of the portfolio, ranked #128.

Valley National Advisers first reported a position in NVS in Q4 2014 and has held it in 46 quarters since. The position peaked at $3.45M in Q3 2016. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Valley National Advisers held 7,859 shares of Novartis worth $1.2M as of Q1 2026.
  • Valley National Advisers sold 30 Novartis shares in Q1 2026, an estimated $4.6K.
  • Novartis made up 0.16% of Valley National Advisers's portfolio in Q1 2026, its #128 holding.
  • Valley National Advisers first reported a position in Novartis in Q4 2014 and has held it in 46 quarters since.
  • Valley National Advisers's Novartis position peaked at $3.45M in Q3 2016.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Valley National Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.